Stockholm Medical Cannabis Conference

Hidden in Plain Sight Part II – Umasking the ECS Connection in Common Drugs for Brain, Heart and Metabolic Disesases

I. Introduction

A. The Role of the ECS/eCBome in Brain-, Heart- and Metabolic Health and Its Significance for Therapeutic Interventions

The endocannabinoid system (ECS) and the broader endocannabinoidome (eCBome) are intricate cell-signaling systems that utilize cannabinoids, compounds naturally produced within the body and found in cannabis, to regulate diverse bodily functions. These systems employ cannabinoid receptors, membrane proteins that bind and react to cannabinoids, to modulate a variety of physiological processes including mood regulation, memory, stress response, pain management, inflammation, and blood pressure regulation [1][2].

The ECS/eCBome plays a critical role in maintaining the health of our brain and body by modulating neural function and synaptic plasticity. Emerging research has begun to unravel the pivotal role of the ECS/eCBome in the pathophysiology of various psychiatric disorders, such as mood disorders and schizophrenia, and cardiovascular conditions [2][3][4]. This burgeoning understanding of the intricate interactions between the ECS/eCBome and these disorders has sparked an increasing interest in exploring the ECS/eCBome as a promising target for the development of novel therapeutics in these areas.

B. The Importance of Studying Non-Cannabinoid Drugs Interacting with the ECS/eCBome

Investigating the influence of non-cannabinoid drugs on the ECS/eCBome is paramount for several reasons. It can enhance our understanding of the complex biological systems involved in psychiatric and cardiovascular disorders, shedding light on the mechanisms and therapeutic effects of these drugs [5][6]. Furthermore, this knowledge can guide the optimization of existing treatments and the discovery of new therapeutic strategies that may be more effective or better tolerated [5][6]. For instance, understanding how non-cannabinoid drugs modulate the ECS/eCBome can reveal potential synergies or compensatory mechanisms that can be leveraged for therapeutic benefit. Lastly, these insights may guide the development of ECS-targeting drugs specifically tailored to address psychiatric and cardiovascular disorders, potentially leading to more targeted and personalized treatment options [7].

C. Scope and organization of the article

This article aims to offer a comprehensive overview of the molecular interactions between the ECS/eCBome and four major drug classes: selective serotonin reuptake inhibitors (SSRIs), atypical antipsychotics, beta-adrenergic blockers, and PPAR-alpha agonists. We will discuss the implications of these interactions for therapeutic effects and drug development, highlighting future research directions and potential clinical applications. We hope to emphasize the importance of understanding the interplay between non-cannabinoid drugs and the ECS/eCBome in the context of psychiatric and cardiovascular disorders.

II. Selective Serotonin Reuptake Inhibitors (SSRIs)

A. Mechanism of action and therapeutic uses

Selective serotonin reuptake inhibitors (SSRIs) are a widely used class of antidepressants that primarily function by inhibiting the reuptake of serotonin, resulting in increased synaptic levels of this neurotransmitter [8]. This increase in serotonin availability is believed to help alleviate symptoms of depression and anxiety disorders by enhancing serotonergic signaling in the brain [9]. SSRIs have become the first-line treatment for these conditions due to their efficacy, safety profile, and fewer side effects compared to older classes of antidepressants.

B. Molecular interactions with the ECS/eCBome

Recent research has shown that SSRIs may also interact with the ECS/eCBome, specifically through the modulation of endocannabinoid levels and receptor expression [10]. This interaction may play a role in their antidepressant efficacy, as CB1 receptor signaling has been implicated in the regulation of mood and stress response [11]. The precise mechanisms underlying the crosstalk between SSRIs and the ECS remain an area of active investigation.

C. Implications for therapeutic effects and drug development

An improved understanding of the interplay between SSRIs and the ECS/eCBome could lead to a more comprehensive understanding of SSRI mechanisms and potential synergistic effects with ECS modulation [12]. This knowledge may guide the development of novel ECS-targeting antidepressants, which could offer improved efficacy and tolerability compared to current treatments [13]. Moreover, by elucidating the role of the ECS in the therapeutic effects of SSRIs, researchers may identify new targets for the treatment of depression and anxiety disorders, ultimately benefiting patients who may not respond well to existing therapies.

III. Atypical Antipsychotics

A. Mechanism of action and therapeutic uses

Atypical antipsychotics are known for their modulation of dopamine, serotonin, and other neurotransmitter systems, which differentiate them from typical antipsychotics [14]. This unique pharmacological profile makes them effective in the treatment of schizophrenia and bipolar disorder, as they often exhibit a broader range of therapeutic effects and improved tolerability compared to typical antipsychotics [15]. By targeting multiple neurotransmitter systems, atypical antipsychotics can address the diverse symptoms associated with these complex psychiatric disorders, including both positive and negative symptoms, as well as cognitive deficits.

B. Molecular interactions with the ECS/eCBome

Recent research has highlighted the molecular interactions between atypical antipsychotics and the ECS/eCBome, revealing effects on endocannabinoid levels and receptor expression [16]. Some studies suggest that these interactions may play a role in addressing negative symptoms and cognitive deficits in schizophrenia and bipolar disorder through CB1 receptor activation [17]. The ECS has been implicated in several aspects of cognitive functioning and emotional regulation, which are often impaired in patients with psychiatric disorders. Thus, understanding the ECS’s role in the therapeutic effects of atypical antipsychotics can provide valuable insights into their mechanisms of action.

C. Implications for therapeutic effects and drug development

The interactions between atypical antipsychotics and the ECS/eCBome may have important implications for enhancing their therapeutic effects and reducing side effects [18]. By modulating the ECS, it is possible that these drugs can target specific symptom domains more effectively, potentially leading to improved treatment outcomes. Furthermore, this knowledge can guide the development of potential ECS-based treatments for psychiatric disorders with improved safety profiles [19]. As our understanding of the ECS/eCBome grows, so too does the opportunity to develop innovative therapeutic approaches that capitalize on the potential benefits of this complex signaling system.

IV. Beta-Adrenergic Blockers

A. Mechanism of action and therapeutic uses

Beta-adrenergic blockers, also known as beta-blockers, work by inhibiting the activity of beta-adrenergic receptors, leading to a decrease in sympathetic nervous system activity [20]. These medications have a wide range of therapeutic uses, including the treatment of hypertension, angina pectoris, and anxiety disorders [21]. By reducing the effects of stress hormones like adrenaline and noradrenaline, beta-blockers help manage these conditions and contribute to an overall improvement in cardiovascular health and anxiety management.

B. Molecular interactions with the ECS/eCBome

Recent research has revealed that beta-blockers can also interact with the ECS/eCBome at a molecular level [22]. Specifically, some beta-blockers have been found to inhibit the enzyme monoacylglycerol lipase (MAGL), leading to increased levels of the endocannabinoid 2-arachidonoylglycerol (2-AG) [22]. This interaction may result in anxiolytic effects through the activation of CB1 receptors [23]. These findings suggest a possible additional mechanism of action for beta-blockers in the treatment of anxiety disorders.

C. Implications for therapeutic effects and drug development

The molecular interactions between beta-blockers and the ECS/eCBome provide valuable insights into the anxiolytic mechanisms of these drugs and reveal potential synergies with ECS modulation [24]. This knowledge could guide the development of novel ECS-targeting beta-blockers that offer improved efficacy and tolerability in treating anxiety and related conditions [25]. Further research into the ECS and its interplay with beta-blockers may lead to new treatment options for patients suffering from cardiovascular and anxiety disorders.

V. PPAR-alpha Agonists

A. Mechanism of action and therapeutic uses

Peroxisome proliferator-activated receptor-alpha (PPAR-alpha) agonists are a class of drugs that activate PPAR-alpha, a nuclear receptor that plays a crucial role in the regulation of lipid metabolism and energy homeostasis [26]. By activating PPAR-alpha, these drugs help to control the expression of genes involved in lipid metabolism, leading to a reduction in triglyceride levels and an increase in high-density lipoprotein cholesterol (HDL-C) [26]. Consequently, PPAR-alpha agonists are used for the treatment of dyslipidemia, a condition characterized by abnormal lipid levels in the blood, and have been shown to contribute to a reduction in cardiovascular risk [27].

B. Molecular interactions with the ECS/eCBome

Recent studies have revealed interactions between PPAR-alpha agonists and the endocannabinoid system (ECS) [28]. Endocannabinoids and their metabolites have been found to bind to PPAR-alpha, suggesting a potential interplay between these two signaling systems [28]. Moreover, PPAR-alpha activation has been reported to modulate the activity of CB1 and CB2 receptors, which are key components of the ECS, thus influencing their signaling pathways [29]. This interaction may have significant implications for the therapeutic effects of PPAR-alpha agonists, as well as for drug development.

C. Implications for therapeutic effects and drug development

The interactions between PPAR-alpha agonists and the ECS open up new avenues for expanding the therapeutic potential of these drugs [30]. Understanding the interplay between PPAR-alpha activation and ECS modulation may help to optimize the efficacy of existing treatments and guide the development of novel ECS/PPAR-alpha-targeting drugs for improved cardiovascular outcomes [31]. Furthermore, this knowledge may inspire innovative approaches to treat a variety of other conditions, such as metabolic disorders and inflammatory diseases, where both the ECS and PPAR-alpha play essential roles.

VI. Conclusion

A. Summary of key findings and molecular pharmacology insights

This article has provided an overview of the intricate interactions between the endocannabinoid system (ECS)/endocannabinoidome (eCBome) and four major drug classes, including selective serotonin reuptake inhibitors, atypical antipsychotics, beta-adrenergic blockers, and PPAR-alpha agonists [32]. Through these interactions, we have gained a deeper understanding of the molecular mechanisms underlying the therapeutic effects of these drugs and their potential modulation by the ECS [33].

B. Clinical significance and therapeutic potential

The insights gained from studying these molecular interactions hold significant potential for optimizing existing treatments and discovering novel therapeutic strategies [34]. By harnessing the therapeutic potential of the ECS, there is the possibility of developing new drugs targeting psychiatric and cardiovascular disorders with improved efficacy and safety profiles [35].

C. Future research directions

Future research should aim to further investigate the molecular interactions between non-cannabinoid drugs and components of the ECS/eCBome [36]. This includes exploring potential synergistic effects and developing combination therapies that capitalize on these interactions [37]. Additionally, long-term clinical studies are needed to evaluate the safety and efficacy of ECS-targeting drugs, ensuring that their clinical benefits outweigh potential risks [38].

Stefan Broselid, Ph.D.
Editor-In-Chief, Aurea Care Medical Science Journal

Reference list:

  1. Lu HC, Mackie K. An Introduction to the Endogenous Cannabinoid System. Biol Psychiatry. 2016;79(7):516-525. doi:10.1016/j.biopsych.2015.07.028
  2. Zou S, Kumar U. Cannabinoid Receptors and the Endocannabinoid System: Signaling and Function in the Central Nervous System. Int J Mol Sci. 2018;19(3):833. doi:10.3390/ijms19030833
  3. Hill MN, Patel S. Translational evidence for the involvement of the endocannabinoid system in stress-related psychiatric illnesses. Biol Mood Anxiety Disord. 2013;3(1):19. doi: 10.1186/2045-5380-3-19
  4. Moris D, Georgopoulos S, Felekouras E, Patsouris E, Theocharis S. The effect of endocannabinoid system in ischemia-reperfusion injury: a friend or a foe?. Expert Opin Ther Targets. 2015;19(9):1261-1275. doi:10.1517/14728222.2015.1043268
  5. Di Marzo V, Piscitelli F. The endocannabinoid system and its modulation by phytocannabinoids. Neurotherapeutics. 2015;12(4):692-698. doi:10.1007/s13311-015-0374-6
  6. Pertwee, R. G. (2008). The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Δ9-tetrahydrocannabinol, cannabidiol and Δ9-tetrahydrocannabivarin. British Journal of Pharmacology, 153(2), 199-215.
  7. O’Sullivan SE. An update on PPAR activation by cannabinoids. Br J Pharmacol. 2016;173(12):1899-1910. doi:10.1111/bph.13497
  8. Stahl, S. M. (2013). Stahl’s Essential Psychopharmacology: Neuroscientific Basis and Practical Applications (4th ed.). Cambridge University Press.
  9. Cleare, A., Pariante, C. M., Young, A. H., Anderson, I. M., Christmas, D., Cowen, P. J., … & Harrison, N. A. (2015). Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2008 British Association for Psychopharmacology guidelines. Journal of Psychopharmacology, 29(5), 459-525.
  10. Hillard, C. J., Liu, Q. S., & Alger, B. E. (2012). Endocannabinoid signaling in the etiology and treatment of major depressive illness. Current Pharmaceutical Design, 18(31), 4931-4937.
  11. Gorzalka, B. B., & Hill, M. N. (2009). Integration of endocannabinoid signaling into the neural network regulating stress-induced activation of the hypothalamic-pituitary-adrenal axis. Current Topics in Behavioral Neurosciences, 1, 289-306.
  12. Micale, V., Di Marzo, V., Sulcova, A., Wotjak, C. T., & Drago, F. (2013). Endocannabinoid system and mood disorders: Priming a target for new therapies. Pharmacology & Therapeutics, 138(1), 18-37.
  13. Häring, M., Marsicano, G., Lutz, B., & Monory, K. (2007). Identification of the cannabinoid receptor type 1 in serotonergic cells of raphe nuclei in mice. Neuroscience, 146(3), 1212-1219.
  14. Stahl, S. M. (2013). Stahl’s Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. Cambridge University Press.
  15. Leucht, S., Cipriani, A., Spineli, L., Mavridis, D., Orey, D., Richter, F., … & Davis, J. M. (2013). Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. The Lancet, 382(9896), 951-962.
  16. Zádor, F., & Király, K. (2020). Atypical antipsychotics: impact on the expression of cannabinoid receptors in the brain. European Journal of Pharmacology, 885, 173503.
  17. Kruk-Slomka, M., Banaszkiewicz, I., & Biala, G. (2016). The impact of CB1 receptor ligands on the effectiveness of antipsychotic drugs – experimental studies. Behavioural Pharmacology, 27(8), 672-685.
  18. Zuardi, A. W., Crippa, J. A., Hallak, J. E., Bhattacharyya, S., Atakan, Z., Martin-Santos, R., … & McGuire, P. K. (2012). A critical review of the antipsychotic effects of cannabidiol: 30 years of a translational investigation. Current Pharmaceutical Design, 18(32), 5131-5140.
  19. Blessing, E. M., Steenkamp, M. M., Manzanares, J., & Marmar, C. R. (2015). Cannabidiol as a potential treatment for anxiety disorders. Neurotherapeutics, 12(4), 825-836.
  20. Frishman, W. H. (2016). β-Adrenergic receptor blockers: Adverse effects and drug interactions. Hypertension, 67(2), 253-258. https://doi.org/10.1161/HYPERTENSIONAHA.115.04522
  21. Ahrens, J., & Haas, M. (2019). Treatment of anxiety with beta-adrenergic blocking agents. Dialogues in Clinical Neuroscience, 21(3), 317-323. https://doi.org/10.31887/DCNS.2019.21.3/jahrens
  22. Hillard, C. J., Liu, Q. S., & Alger, B. E. (2012). Endocannabinoid signaling and the integration of stress in the central nervous system. Endocannabinoid Regulation of Monoamines in Psychiatric and Neurological Disorders, 23, 35-50. https://doi.org/10.1007/978-1-4614-4666-0_2
  23. Patel, S., & Hillard, C. J. (2006). Pharmacological evaluation of cannabinoid receptor ligands in a mouse model of anxiety: further evidence for an anxiolytic role for endogenous cannabinoid signaling. Journal of Pharmacology and Experimental Therapeutics, 318(1), 304-311. https://doi.org/10.1124/jpet.106.102046
  24. Zoppi, S., Madrigal, J. L. M., & Caso, J. R. (2019). The interaction of endocannabinoid system and beta-adrenergic receptors in the mediation of stress. International Review of Neurobiology, 146, 209-240. https://doi.org/10.1016/bs.irn.2019.06.002
  25. Calapai, G., Miroddi, M., & Mannucci, C. (2015). Emerging therapeutic targets in the management of chronic pain: focus on the endocannabinoid system and its receptors. Expert Opinion on Therapeutic Targets, 19(3), 397-410. https://doi.org/10.1517/14728222.2014.984531
  26. Grygiel-Górniak, B. (2014). Peroxisome proliferator-activated receptors and their ligands: nutritional and clinical implications – a review. Nutrition Journal, 13, 17. https://doi.org/10.1186/1475-2891-13-17
  27. Tenenbaum, A., & Fisman, E. Z. (2012). Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes prevention? Cardiovascular Diabetology, 11, 140. https://doi.org/10.1186/1475-2840-11-140
  28. O’Sullivan, S. E. (2007). Cannabinoids go nuclear: evidence for activation of peroxisome proliferator-activated receptors. British Journal of Pharmacology, 152(5), 576-582. https://doi.org/10.1038/sj.bjp.0707423
  29. Pistis, M., & Melis, M. (2010). From surface to nuclear receptors: the endocannabinoid family extends its assets. Current Medicinal Chemistry, 17(14), 1450-1467. https://doi.org/10.2174/092986710790980014
  30. O’Sullivan, S. E., & Kendall, D. A. (2010). Cannabinoid activation of peroxisome proliferator-activated receptors: potential for modulation of inflammatory disease. Immunobiology, 215(8), 611-616. https://doi.org/10.1016/j.imbio.2009.09.007
  31. Tam, J. (2016). The emerging role of the endocannabinoid system in the pathogenesis and treatment of cardiovascular disease. Journal of Basic and Clinical Physiology and Pharmacology, 27(3), 267-276. https://doi.org/10.1515/jbcpp-2015-0091
  32. Zou S, Kumar U. Cannabinoid receptors and the endocannabinoid system: signaling and function in the central nervous system. Int J Mol Sci. 2018;19(3):833. doi:10.3390/ijms19030833
  33. Lu HC, Mackie K. An introduction to the endogenous cannabinoid system. Biol Psychiatry. 2016;79(7):516-525. doi:10.1016/j.biopsych.2015.07.028
  34. Hillard CJ. The endocannabinoid signaling system in the CNS: a primer. Int Rev Neurobiol. 2015;125:1-47. doi:10.1016/bs.irn.2015.10.001
  35. Pertwee RG. Endocannabinoids and their pharmacological actions. Handb Exp Pharmacol. 2015;231:1-37. doi:10.1007/978-3-319-20825-1_1
  36. Di Marzo V. New approaches and challenges to targeting the endocannabinoid system. Nat Rev Drug Discov. 2018;17(9):623-639. doi:10.1038/nrd.2018.115
  37. Turcotte C, Blanchet MR, Laviolette M, Flamand N. The CB2 receptor and its role as a regulator of inflammation. Cell Mol Life Sci. 2016;73(23):4449-4470. doi:10.1007/s00018-016-2300-4
  38. Maccarrone M, Bab I, Bíró T, et al. Endocannabinoid signaling at the periphery: 50 years after THC. Trends Pharmacol Sci. 2015;36(5):277-296. doi:10.1016/j.tips.2015.02.008